Rational Design of Hybrid SARS-CoV-2 Main Protease Inhibitors Guided by the Superimposed Cocrystal Structures with the Peptidomimetic Inhibitors GC-376, Telaprevir, and Boceprevir
Zilei Xia(University of Arizona), Jun Wang(Rutgers Sexual and Reproductive Health and Rights), Yanmei Hu(University of Arizona), Chunlong Ma(University of Arizona), Yan Xiang(Sichuan University), Xiangzhi Meng(University of California, Los Angeles), Fushun Zhang(The University of Texas at San Antonio Health Science Center), Yu Chen(University of South Florida), Tommy Szeto(University of Arizona), M. Sacco(University of South Florida)
Cited by 102
Related Papers
Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against M <sup>pro</sup> and cathepsin L
|Science Advances|2020|400
Clofazimine broadly inhibits coronaviruses including SARS-CoV-2
|Nature|2021|216
Discovery of SARS-CoV-2 Papain-like Protease Inhibitors through a Combination of High-Throughput Screening and a FlipGFP-Based Reporter Assay
|ACS Central Science|2021|200
The <i>in vitro</i> antiviral activity of lactoferrin against common human coronaviruses and SARS-CoV-2 is mediated by targeting the heparan sulfate co-receptor
|Emerging Microbes & Infections|2021|190
Expedited Approach toward the Rational Design of Noncovalent SARS-CoV-2 Main Protease Inhibitors
|Journal of Medicinal Chemistry|2021|168